126485-55-0Relevant academic research and scientific papers
Method for synthesizing AMG837
-
Paragraph 0054; 0056-0059, (2020/01/03)
The invention relates to a method for synthesizing a compound, in particular to a method for synthesizing AMG837. The method comprises the following steps: a step of preparing an intermediate D by a reaction of an intermediate E with propyne; a step of de
Method for synthesizing alkyne through catalytic asymmetric cross coupling (by machine translation)
-
Paragraph 1012, (2020/01/12)
The invention belongs to the field of, asymmetric synthesis, and discloses a method for catalyzing asymmetric cross- coupling to synthesize: an alkyne, and the L method comprises, the following steps, of A: preparing B a cuprous, salt and C a: ligand; preparing a catalyst; adding a base; reacting the compound with the compound with the compound; and reacting the compound with the compound. Of these, one of them, X is selected from the group consisting of, R halogens. 1 Optionally substituted heteroarylsulfonylcyanamide groups selected from the, group consisting, of optionally substituted, phenyl groups In-flight vehicle, R6 Trialkyl silyl groups or alkyl radicals, R2 Cycloalkyl radicals optionally substituted with an, optionally substituted alkyl, (CH radical2 )n R4 Multi,layer chain, n＝0-10,R saw blade4 A group selected, from, the group consisting of phenyl, alkenyl, aralkynyls, noonyloxy,and, noonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulphonylsulphonylsulphonylsulphonylsulphonylsulphonylsulphonylsulphonylsulphonylsulphonylphenyl disiloxy-radicals. R3 A ligand, selected from hydrogen or any of the functional groups, is selected from the group consisting of, hydrogen and any L other functional group. The method, R disclosed by the, A invention has the, advantages of good catalytic, R ’ effect, wide application range. and high catalytic efficiency, and the, method disclosed by the, invention has the. advantages of good catalytic effect, wide application range and high catalytic efficiency. (by machine translation)
IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
-
Paragraph 00132; 00134, (2013/11/18)
The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W,Y, R0, R2, R4, Ra, Rb, X1, X2, X3 and X4 are as defined herein,, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS
-
Page/Page column 85, (2013/09/12)
The present invention relates to phenyl alkanoic acid derivatives (the compounds of Formula (I)); and their isotopic forms, stereoisomeric and tautomeric forms and mixtures thereof in all ratios, or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, prodrugs, polymorphs, N-oxides, S-oxides or carboxylic acid isosteres thereof. The invention also relates to processes for the preparation of compounds of Formula (I) and pharmaceutical compositions comprising one or more of the compounds of Formula (I). The said compounds and the pharmaceutical composition function as GPR (G-protein coupled receptor) agonists, particularly as GPR40 agonists, and are useful in the treatment of diseases or conditions mediated by GPR40. The present invention further relates to a method of treatment of diseases or conditions mediated by GPR40comprising administering to a subject in need thereof a therapeutically effective amount of the compounds of Formula (I).
AMG 837: A potent, orally bioavailable GPR40 agonist
Houze, Jonathan B.,Zhu, Liusheng,Sun, Ying,Akerman, Michelle,Qiu, Wei,Zhang, Alex J.,Sharma, Rajiv,Schmitt, Michael,Wang, Yingcai,Liu, Jiwen,Liu, Jinqian,Medina, Julio C.,Reagan, Jeff D.,Luo, Jian,Tonn, George,Zhang, Jane,Lu, Jenny Ying-Lin,Chen, Michael,Lopez, Edwin,Nguyen, Kathy,Yang, Li,Tang, Liang,Tian, Hui,Shuttleworth, Steven J.,Lin, Daniel C.-H.
supporting information; experimental part, p. 1267 - 1270 (2012/03/26)
The discovery that certain long chain fatty acids potentiate glucose stimulated insulin secretion through the previously orphan receptor GPR40 sparked interest in GPR40 agonists as potential antidiabetic agents. Optimization of a series of β-substituted p
Enantioselective synthesis of a GPR40 agonist AMG 837 via catalytic asymmetric conjugate addition of terminal alkyne to α,β-unsaturated thioamide
Yazaki, Ryo,Kumagai, Naoya,Shibasaki, Masakatsu
, p. 952 - 955 (2011/04/25)
A concise enantioselective synthetic route to a potent GPR40 agonist AMG 837 is described. The crucial catalytic asymmetric conjugate addition of terminal alkyne was promoted by a soft Lewis acid/hard Bronsted base cooperative catalyst, allowing efficient
Development of a scalable synthesis of a GPR40 receptor agonist
Walker, Shawn D.,Borths, Christopher J.,Divirgilio, Evan,Huang, Liang,Liu, Pingli,Morrison, Henry,Sugi, Kiyoshi,Tanaka, Masahide,Woo, Jacqueline C. S.,Faul, Margaret M.
experimental part, p. 570 - 580 (2011/12/04)
Early process development and salt selection for AMG 837, a novel GPR40 receptor agonist, is described. The synthetic route to AMG 837 involved the convergent synthesis and coupling of two key fragments, (S)-3-(4-hydroxyphenyl) hex-4-ynoic acid (1) and 3-
HETEROCYCLIC GPR40 MODULATORS
-
Page/Page column 108, (2008/06/13)
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS
-
Page/Page column 84-85, (2008/06/13)
Compounds having the general formula I and/or the general formula II are useful, for example, for treating metabolic disorders in a subject formula (I) (II) where the variables are provided herein. Compositions and methods for using the compounds for preparing medicaments and for treating metabolic disorders such as, for instance, type II diabetes are disclosed.
Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
-
Page/Page column 18, (2008/06/13)
The present invention provides compounds useful, for example, for modulating insulin levels in a subject, having the general formula I: wherein Q is an optionally substituted phenyl; L is a bond or O; P is a benzene or an optionally substituted thiazole r
